Patent ID: 6906170

Claim:
A synthetic anti-inflammatory peptide of IL-2 or an anti-inflammatory derivative thereof, which inhibits in vitro: (i) adhesion of activated T cells to fibronectin, laminin and/or collagen-type IV; (ii) chemotactic migration of T cells through fibronectin; and/or (iii) spontaneous or TNF-α-induced secretion of IL-8 or IL-1β, from intestinal epithelial cells, selected from the group consisting of: (i) peptides pep1, pep2, and pep3 consisting of the sequences: (pep1) Ile-Val-Leu (pep2) Glu-Phe-Leu-Asn-Arg-Trp-Ile-Thr (SEQ ID NO:1) (pep3) Arg-Met-Leu-Thr (SEQ ID NO:2) (ii) peptides obtained from pep2 by deletion of one or more amino acid residues; (iii) peptides obtained by addition to peptides (i) or (ii) of one or more natural or non-natural amino acid residues to the N-terminus and/or C-terminus; (iv) peptides obtained by replacement of one amino acid residue of peptides (i) to (iii) by another natural amino acid residue or by a non-natural amino acid residue; (v) peptides of (i) to (iii) which are all-L, all-D or a combination of D- and L-amino acid residues; (vi) amide derivatives of the C-terminal residue of peptides (i) to (v); (vii) cyclic derivatives of peptides (i) to (vi) in which the peptide is cyclized by an intramolecular bond; and (viii) dual peptides consisting of two of the same or combination of peptides (i) to (vii), wherein the two peptides are covalently linked to one another directly or through a spacer.